Prophylactic rhTPO Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiotherapy in Limited-Stage SCLC:A Prospective, Multicenter, Phase II Clinical Trial

Prophylactic rhTPO during CCRT for patients with LS-SCLC demonstrated a potential benefit in maintaining platelet counts with a low incidence of CTIT. These findings support further investigation of rhTPO as a preventive strategy for high-risk CTIT patients.